-+ 0.00%
-+ 0.00%
-+ 0.00%

Climb Bio Inc. Outlines 2026 Strategy With Multiple Clinical Trial Readouts, Expanded Pipeline in Immune-Mediated Diseases, and Financial Guidance Extending Operations Into 2028

路透·01/08/2026 12:08:29

登錄查看新聞詳情